Effective treatment of neuroendocrine tumors With temozolomide and capecitabine

Authors:

Abstract
4216 Background: Low grade neuroendocrine tumors (NET), which are differentiated and metastatic, have a poor response to chemotherapy (<10%). This group (7000 cases per year in the U.S.) includes carcinoid tumors, pancreatic endocrine tumors (PETs), catecholamine-secreting tumors (e.g. pheochromocytomas), medullary carcinoma of the thyroid and excludes small cell cancers of the lung and GI tract. In our lab, we have found that capecitabine (5-FDUR), an oral pro-drug for 5-FU, and temozolomide are synergistic for induction of apoptosis in 2 human NET cell lines when given in a specific sequence and schedule. Our hypothesis is that the DNA damage induced by capecitabine, by incorporation of 5-FdUTP into DNA and reducing thymidine pools by inhibition of thymidylate synthase via 5-FdUMP, synergistically potentiates the effect of temozolomide on O6-alkylguanyl alkyl-transferase (O6-AGAT). Methods: We have treated ten patients with progressive metastatic NET who had failed chemotherapy and/or octreotide. Treatm...